Acerta Pharma Bv

This study tested a new oral medication called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) and related blood cancers that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and see if the drug could shrink the canc…

This early-stage study is testing whether adding a new drug called acalabrutinib to standard lymphoma treatments is safe and effective for people with mantle cell lymphoma. The trial involves 72 adults who either haven't received treatment before or whose cancer has returned. Res…

This study is testing a drug called acalabrutinib, both by itself and combined with other cancer drugs, for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to prior treatment. The main goals are to check the safety of these drug combinations and to se…

This study tested a daily oral medication called acalabrutinib for people with Waldenström macroglobulinemia, a rare type of blood cancer. It involved 107 adults, including those whose cancer returned after prior treatment and some newly diagnosed patients. The main goal was to s…

This study tested an oral medication called ACP-196 (acalabrutinib) for people with mantle cell lymphoma that has returned or stopped responding to previous treatments. Participants took the medication twice daily for as long as it worked and was tolerated. The main goal was to m…

This large, late-stage study is testing whether adding a newer targeted drug (acalabrutinib) to a standard two-drug chemotherapy regimen (bendamustine and rituximab) works better for people newly diagnosed with mantle cell lymphoma. It will compare how long patients live without …

This is an early safety study for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. It is testing a new drug, AZD6738, given alone and in combination with an existing drug, acalabrutinib. The …

This large, late-stage study is testing whether adding a newer targeted drug called acalabrutinib to a standard chemotherapy regimen (R-CHOP) works better for people under 75 with a specific, harder-to-treat type of aggressive lymphoma. The main goal is to see if the new combinat…

This study tested a drug called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to treatment, and who could not tolerate the standard drug ibrutinib. It involved 60 participants and aimed to see if acalabrutinib could shrin…

This study tested whether a newer drug, acalabrutinib, works better than standard drug combinations for adults whose chronic lymphocytic leukemia (CLL) has returned or stopped responding to prior treatment. It directly compared how long patients lived without their cancer getting…

This study tested an experimental drug called acalabrutinib (ACP-196) in adults whose aggressive brain cancer (glioblastoma) had returned after one or two prior treatments. The goal was to see if the drug could shrink tumors and was safe for these patients. It was an early-stage …

This study compares two targeted drugs, acalabrutinib and ibrutinib, for adults with a hard-to-treat form of chronic lymphocytic leukemia (CLL) who have already had at least one prior therapy. The main goal is to see if acalabrutinib can keep the cancer from getting worse for as …